コミュニティに住む高齢者のプロドロマール・パーキンソン病とドーパミン神経伝送の特徴
Lana Chahine1, Andrea L Rosso2, Ian Troidl2
1Department of Neurology, School of Medicine, University of Pittsburgh, PA.
Neurology
|August 29, 2025
まとめ
プロドロマル・パーキンソン病 (PD) の症状は高齢者に多く見られ,脳内のドーパミン濃度の低下と関連しています. これらの早期の指標を特定することで 一般集団におけるPDリスクを検出できます
科学分野:
- 神経学
- 神経イメージング
- 高齢者医療
背景:
- パーキンソン病 (PD) の病理は,臨床診断の数年前から始まることがあります.
- 臨床試験の適格性には,プロドロマの段階で個人を特定することが重要です.
- 以前の研究ではPDプロドロームの特徴が記述されたが,未選択の高齢者におけるドーパミナージック神経末端密度とのインビボの関連は検証されなかった.
研究 の 目的:
- コミュニティに住む高齢者のPDリスク因子とプロドロマの兆候/症状の流行を決定する.
- これらのプロドロマの特徴とニグロストリアタルドパミナージック神経末端の密度との関係を調べる.
- 他の潜在的プロドロマ・PDの特徴の流行と分布を調査する.
主な方法:
- 診断された神経疾患のない231人のコミュニティに住む高齢者の横断的観察研究.
- 5つのPDリスクマーカーと最大8つのプロドロマ症状の評価
- [11C](+) -α-DTBZ PETを用いたドーパミナー画像は,ニゴロストリアルドーパミンの末端密度を測定し,プロドロマルPDの確率を計算する.
主要な成果:
- 参加者の半数以上 (56. 7%) は,プロドロマの兆候/症状が1つ以上あり,最も一般的なのが認知障害でした.
- 可能性のあるプロドロマ PD (pPD) は,サンプル7. 8%で特定されました.
- pPDの患者では,pPDのない患者と比較して,DTBZ結合が著しく低く,非対称性が顕著でした. 低血症は結合の減少と関連していた.
結論:
- プロドロマ・ノンモーターおよびモーターのPDの徴候/症状は,コミュニティに住む高齢者に多く見られます.
- プロドロマのPDの確率は,後部パウタメンにおけるドーパミナージック神経末端の密度が低下し,非対称である.
- プロドロマ特性の複合的な測定は,集団レベルでリスクのある個人を特定するのに役立ちます.
関連する概念動画
01:15Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
01:24Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:37Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
945
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
945